Abstract
Background Predictors of treatment outcome in major depressive disorder (MDD) could contribute to evidence-based therapeutic choices. This study tested the cost-effectiveness of a pharmacogenetic and clinical predictive model (PGx-CL-R) vs a clinical risk (CL-R) predictive model in guiding the assignment of combined pharmacotherapy and psychotherapy vs pharmacotherapy in MDD.
Methods We hypothesized that the prescription of combined treatment, a strategy with evidence of increased efficacy vs pharmacotherapy, may be optimized based on the baseline risk of pharmacotherapy resistance, estimated through PGx-CL-R or CL-R predictive models. Both strategies were compared to standard care (ST, pharmacotherapy to all subjects). Treatment effects, costs and utilities (quality adjusted life years, QALYs) were based on the literature and included in a three-years Markov model.
Results CL-R was cost-effective compared to PGx-CL-R, with ICER (incremental cost effect ratio) of £2341 (CL-R) and £3937 (PGx-CL-R) per QALY compared to ST. PGx-CL-R had similar or better ICER compared to ST only when 1) the cost of genotyping was £100 per subject or less or 2) the sensitivity of the PGx-CL-R test was at least 0.90 and the specificity at least 0.85. CL-R had ICER of £3664 and of £4110 when the CL-R model was tested in two independent samples.
Limitations lack of validation in clinical trial.
Conclusions Prediction of pharmacotherapy resistance according to clinical risk might be a cost-effective strategy if confirmed on large samples from the general population. Combined treatment with drugs having a very good tolerability profile could be a cheaper alternative to psychotherapy.
Competing Interest Statement
Dr. Souery D. has received grant/research support from GlaxoSmithKline and Lundbeck; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen and Lundbeck. Prof. Montgomery S. has been a consultant or served on Advisory boards: AstraZeneca, Bristol Myers Squibb, Forest, Johnson & Johnson, Leo, Lundbeck, Medelink, Neurim, Pierre Fabre, Richter. Prof. Kasper S. received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Prof. Zohar J. has received grant/research support from Lundbeck, Servier, Brainsway and Pfizer, has served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca and Roche, and has served on speakers’ bureaus for Lundbeck, Roch, Lilly, Servier, Pfizer and Abbott. Prof. Mendlewicz J. is a member of the Board of the Lundbeck International Neuroscience Foundation and of Advisory Board of Servier. Prof. Serretti A. is or has been consultant/speaker for: Abbott, Abbvie, Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier. Cathryn Lewis is a member of the R&D SAB of Myriad Neuroscience. The other authors declare no conflict of interest.
Clinical Trial
n/a
Funding Statement
Chiara Fabbri is supported by a Marie Skłodowska-Curie Actions Individual Fellowship funded by the European Community (EC Grant agreement number: 793526; project title: Exome Sequencing in stages of Treatment Resistance to Antidepressants - ESTREA). Cathryn M. Lewis is part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The collection of the main sample included in this study and TRD2 sample was supported by an unrestricted grant from Lundbeck for the Group for the Study of Resistant Depression (GSRD). Lundbeck had no further role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. All authors were actively involved in the design of the study, the analytical method of the study, the selection and review of all scientific content. All authors had full editorial control during the writing of the manuscript and approved it. The GENDEP project was supported by a European Commission Framework 6 grant (contract reference: LSHB-CT-2003-503428). The Medical Research Council, United Kingdom, and GlaxoSmithKline (G0701420) provided support for genotyping. This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. High performance computing facilities were funded with capital equipment grants from the GSTT Charity (TR130505) and Maudsley Charity (980).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This study used previously published results to to create a Markov simulation.